Company news

Liaoning Chengda Biotechnology Co. Ltd. news in 2026

Liaoning Chengda Biotechnology Co. Ltd.'s news releases, calls and decks from 2026, newest first.

View company

(688739)"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Announcement on Shareholdings of Top 10 Shareholders and Top 10 Shareholders Holding Unrestricted Shares Concerning Share Repurchase

November 16, 2026

(688739)"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Notice on Convening the 3rd Extraordinary General Meeting in 2026

November 10, 2026

(688739)"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Announcement on Share Repurchase Plan through Call Auction

November 10, 2026

(688739)"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Announcement on Resolutions of the 33rd Meeting of the 5th Board of Directors

November 10, 2026

(688739)"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Announcement on Adjustment of Certain Sub-projects of Raised Funds Investment Projects, Termination of Certain Raised Funds Investment Projects, and Continued Deposit of Surplus Raised Funds in Special Account for Raised Funds

November 10, 2026

(688739)"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Report for Q3 2026

October 29, 2026

(688739)"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Announcement on Subscription for Private Fund Units and Related Party Transaction

October 29, 2026

(688739)"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026

October 13, 2026

(688739)"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Announcement on Cancellation of Certain Repurchased Shares, Reduction of Registered Capital and Notice to Creditors

October 13, 2026

Announcement on Change of Registered Capital and Amendments to the Articles of Association

September 24, 2026

Announcement on Expiration of Shareholding Reduction Plan of Senior Executive and Results of Shareholding Reduction

September 21, 2026

Announcement on Convening the 2026 Semi-annual Performance Briefing

September 14, 2026

Special Report on the Deposit and Actual Use of Raised Funds for the First Half of 2026

August 24, 2026

Announcement on the Results of the Special Governance Review by the Audit Committee of the Board of Directors

August 20, 2026

Announcement on the Initiation of Phase I Clinical Trial for Influenza Vaccine (Split Virion, High-Dose)

July 17, 2026

Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report

July 10, 2026

Announcement on the Influenza Virus Split Vaccine Obtaining Drug Registration Certificate and Passing GMP Compliance Inspection

July 2, 2026

Announcement on Obtaining Drug Registration Certificate for Quadrivalent Influenza Vaccine (Split Virion) and Passing GMP Compliance Inspection for Drugs

June 16, 2026

Announcement on Implementation Result of Shares Repurchase and Share Changes

June 11, 2026

Announcement on Progress in Joint Investment with the Controlling Shareholder and Its Wholly-owned Subsidiary and Related Party Transactions

June 5, 2026

Announcement on Progress in Repurchasing Shares through Call Auction

June 2, 2026

Announcement on Shareholding Reduction Plan for Senior Management Members

May 28, 2026

Announcement on Implementation of Dividend Distribution for 2025

May 27, 2026

Announcement on Resolutions of the 2025 Annual General Meeting

May 12, 2026

Announcement on Convening Performance Briefing for 2025 and Q1 2026

April 28, 2026

Announcement on 2025 Annual Profit Distribution Plan

April 20, 2026

Announcement on Obtaining the Approval for Supplementary Application for Drugs for the Core Product Freeze-dried Rabies Vaccine (Vero Cells)

April 17, 2026

Announcement on the Resignation of Independent Directors upon Expiration of Their Term

March 17, 2026

Announcement on Wholly-owned Subsidiary's Passing GMP Compliance Inspection for Drugs

March 9, 2026

Announcement on Preliminary Earnings Estimate for 2025

February 27, 2026

Announcement on Obtaining the Drug Registration Certificate for Freeze-dried Rabies Vaccine (Human Diploid Cell)

February 24, 2026

Announcement on Obtaining Notice of Approval for Drug Clinical Trials for Influenza Virus Split Vaccine (High Dose)

February 12, 2026

Announcement on Outward Investing in Establishing a Wholly-owned Subsidiary

January 26, 2026

Announcement on Subsidiary Opening a Special Account for Raised Funds and Signing a Tripartite Supervision Agreement on Special Account Deposit of Raised Funds

January 5, 2026

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025

December 31, 2025